Biogen Appoints Camille Lee as SVP, Alzheimer’s Disease Therapeutic Area
In her new role, Ms. Lee will be responsible for the design and execution of commercial strategy for the company’s late-stage Alzheimer’s disease assets and will work in partnership with Biogen’s Research & Development function in overseeing Biogen’s entire Alzheimer’s portfolio. She will be based in Cambridge, Mass., and report directly to Chief Medical Officer Alfred Sandrock, Jr., M.D., Ph.D.
Ms. Lee brings to Biogen more than 30 years of industry experience. In her most recent role as Senior Vice President, Diabetes & Obesity Marketing at Novo Nordisk, she led a team of more than 500 professionals while overseeing the marketing of all in-line and future brands as well as market access strategy. During her time in this position, Novo Nordisk successfully launched two brands that achieved leadership in their therapeutic areas.
“Camille’s experience in preparing markets and launching products for highly prevalent diseases will serve us well as we aspire to move toward commercializing our late-stage Alzheimer’s disease candidates,” said Dr. Sandrock. “Her track record aligns perfectly with our mission to deliver transformative therapies for neurodegenerative diseases to patients who desperately need them.”
Prior to taking a leadership role for Novo Nordisk’s diabetes and obesity franchises, Ms. Lee worked across the organization. Her tenure at Novo Nordisk included positions of increasing responsibility in such functions as competitor intelligence, product launch planning, and international marketing for multiple endocrine products.
“Biogen’s R&D in Alzheimer’s is an inspiration, and I am honored to be joining a company that has such an unwavering commitment to the community,” said Ms. Lee. “I look forward to working with the team as we aim to bring therapies to the market that could make a difference to the thousands of patients and their families that we serve.”
Ms. Lee holds a B.S. in Business Administration from California State University, Long Beach, and an M.B.A. from Copenhagen International Management Institute.
Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. Founded in 1978, Biogen is a pioneer in biotechnology, and today the company has the leading portfolio of medicines to treat multiple sclerosis; has introduced the first and only approved treatment for spinal muscular atrophy; and is at the forefront of neurology research for conditions including Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis. Biogen also manufactures and commercializes biosimilars of advanced biologics. For more information, please visit www.biogen.com. Follow us on social media – Twitter, LinkedIn, Facebook, YouTube.
Biogen Safe Harbor
This press release contains forward-looking statements, made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements relating to Biogen’s business activities, the potential of Biogen’s commercial business and pipeline programs, , and the expected benefits from Ms. Lee’s appointment as our Senior Vice President, Alzheimer’s Therapeutic Area. These forward-looking statements may be accompanied by words such as “aim,” “anticipate,” “believe,” “could,” “estimate,” “except,” “forecast,” “intend,” “may,” “plan,” “potential,” “possible,” “will,” and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. You should not place undue reliance on these statements.
These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including, without limitation: risks relating to management and key personnel changes; failure to compete effectively; difficulties in obtaining and maintaining adequate coverage, pricing, and reimbursement for our products; potential future healthcare reforms; the occurrence of adverse safety events; failure to protect and enforce our data, intellectual property, and other proprietary rights and uncertainties relating to intellectual property claims and challenges; uncertainty of success in developing, licensing, or acquiring other product candidates or additional indications for existing products; delay in approval of our drug candidates; product liability claims; and third party collaboration risks. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. Investors should consider this cautionary statement, as well as the risk factors identified in Biogen’s most recent annual or quarterly report and in other reports Biogen has filed with the U.S. Securities and Exchange Commission. These statements are based on our current beliefs and expectations and speak only as of the date of this press release. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.